Hyperactive (Autoimmunity) vs. Dysfunctional (Cancer) T Cells: Two Sides of the Same Coin
ISEF · 2026 Cellular and Molecular Biology
Overview
Cancer and autoimmune diseases present an immunological paradox: T cells adopt opposing functional states. In cancer, T cells become dysfunctional and lose effector function, failing to eliminate malignant cells. In autoimmune diseases like type 1 diabetes (T1D), T cells become hyperactive and inappropriately destroy healthy tissue. Despite chronic antigen stimulation in both inflammatory environments, we observe divergent T cell fates. This study examined what drives T cell dysfunction versus hyperactivation and how hyperactive T cells may behave in the tumor environment (TME) under chronic antigen stimulation. To test this, I utilized a novel mouse model that contains both autoimmunity (T1D) and cancer (SL01-fibrosarcoma). I engineered the SL01 cell line to overexpress IGRP, the target antigen for hyperactive T cells. SL01/IGRP and empty vector control cell lines were implanted; IGRP-expressing tumors regressed, while controls grew progressively. Immunophenotyping of tumors showed a progressive infiltration of IGRP-specific T cells in IGRP-expressing tumors, which were absent in the empty vector tumors. These results suggest that IGRP-specific T cells maintain a hyperactive/cytotoxic state in the tumor despite chronic antigen stimulation in the TME, which is known to drive T cell dysfunction. These findings suggest that there are intrinsic regulatory mechanisms that allow the hyperactive T cells to persist under conditions that normally lead to dysfunction. Programs that drive hyperactivation or dysfunction could be harnessed to reverse or prevent T cell dysfunction in cancer or hyperactivation in autoimmunity. Future studies will utilize ATAC-seq and transcriptomics to better understand the unique regulators of T cell fates.
Awards (1)
- Second Award of $2,400 $2,400
Competition history
- ISEF 2026
Resources
Related projects
JSHS · 2022
KANSAS-NEBRASKA-OKLAHOMA The Protective Role of NKG2D in Type 1 Diabetes Autoimmunity
ISEF · 2020
An In-Depth Look into Identifying the Differentiation Pathway and Cell Type of Dual-Receptor Expressing Lymphocytes in Type 1 Diabetes
ISEF · 2015
On a Mission: Rescuing T-Cells to Fight Cancer
ISEF · 2019
Reversing Tumor-Induced T Cell Suppression through Activation of TLR8 Pathway
ISEF · 2017
The Mutagenesis of the PD-L1 Inhibitory Ligand to Identify the Binding Site of the Novel PD-L1/B7-1 Pathway
ISEF · 2024
Comparing the Functional Capacity and Transcriptional Profiles of Chimeric Antigen Receptor (CAR) T Cells and Bispecific T Cell Engagers (BiTEs)
JSHS · 2020
The effect of anti-PD1 and anti-PDL1 on the cytokine profile and immune system
ISEF · 2014
Investigating the Opposing Roles of Oncoprotein gC1qR and Tumor Suppressive cC1qR as Mechanisms for Inhibiting Cancer Pathogenesis
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair